Stellar Biotechnologies, Inc. Announces Meeting and Record Date and Approval of Advance Notice Policy
27 déc. 2013 16h00 HE
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Dec 27, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that it will hold an annual general and...
Stellar Biotechnologies Announces Patents for Clostridium Difficile Immunotherapy Technology Issued in U.S. and China
09 déc. 2013 09h05 HE
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Dec 9, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of Keyhole...
Stellar Biotechnologies to Host Corporate Update Conference Call and Webcast on December 11
03 déc. 2013 09h05 HE
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Dec 3, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of Keyhole...
Stellar Biotechnologies Appoints Mark A. McPartland as Vice President of Corporate Development and Communications
20 nov. 2013 09h05 HE
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Nov 20, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the appointment of Mark A. McPartland...
Stellar Biotechnologies Presents Preclinical Poster on Clostridium Difficile Active Immunotherapy at Vaccine Congress
28 oct. 2013 09h05 HE
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Oct 28, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the presentation of a preclinical...
Stellar Biotechnologies Immunotherapy Technology Demonstrates Protection Against Clostridium Difficile Infection in Preclinical Study
21 oct. 2013 09h05 HE
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Oct 21, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today presentation of positive results from...
Stellar Biotechnologies Acquires Exclusive, Worldwide License to Clostridium Difficile Immunotherapy Technology
30 juil. 2013 09h05 HE
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Jul 30, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has acquired the...